# A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Source: https://onco.cc/trials/nct06832202/  
OnCo record `nct06832202` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HLX22 and Trastuzumab deruxtecan in HER2-positive breast cancer, run by Shanghai Henlius Biotech, now recruiting.

## Summary

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients is a phase 2 interventional study registered as NCT06832202 by Shanghai Henlius Biotech, with 50 participants planned, started 2025-04-16 and due to reach its primary completion in 2027-06-01. Interventions recorded: HLX22 and Trastuzumab Deruxtecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06832202
- Phase: 2
- Setting: A Phase II Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab Deruxtecan (T-DXd) in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients With Intolerable Adverse Reaction or Disease Progression on Standard of Care
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06832202: https://clinicaltrials.gov/study/NCT06832202

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [HLX22](https://onco.cc/drugs/hlx22/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct06832202.json